Tag: half

Communiqué Orange : Signing of a Memorandum of Understanding for the acquisition of SFR

Press release
Paris, 6 June 2026

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Press release – No. 13 / 2026

Long Table Growth Corp. Announces Closing of $172.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option in Full

DALLAS, TX, June 05, 2026 (GLOBE NEWSWIRE) -- Long Table Growth Corp. (Nasdaq: LTGRU) (the “Company”) today announced the closing of its initial public offering of 17,250,000 units, which includes 2,250,000 units issued pursuant to the exercise by the underwriter of its over-allotment option in full, at a public offering price of $10.00 per unit. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share.

Top Two Spots in American Banker’s 50 Top Innovators in Finance Awarded to CEOs of Vantage Bank and Custodia, Hazel Network’s Co-Founders

Vantage Bank CEO Jeff Sinnott and Custodia CEO Caitlin Long secure the #1 and #2 spots in American Banker's inaugural "The Most Innovative People...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsHalf

KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

Tag: half

Communiqué Orange : Signing of a Memorandum of Understanding for the acquisition of SFR

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Long Table Growth Corp. Announces Closing of $172.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option in Full

Top Two Spots in American Banker’s 50 Top Innovators in Finance Awarded to CEOs of Vantage Bank and Custodia, Hazel Network’s Co-Founders

PXN Unveils All-New High-Linearity Modular NAVOS Flight Series at FlightSimExpo 2026

BIC: Disclosure of total number of voting rights and number of shares forming the capital as of 31 May 2026

BIC: Disclosure Of Trading In Own Shares For May 2026

Twenty-Three Kilometres of Veins in Argentina: Golden Goose Lines Up the Drill

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us